{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:17:05Z","timestamp":1793171825818,"version":"4.5.0"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,10,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>A phase II study was performed to determine the efficacy of irinotecan (IRN) in children with refractory solid tumors. Secondary objectives were to evaluate toxicity, pharmacokinetics, pharmacodynamics, and UGT1A1 genotype.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>A total of 181 patients were enrolled, of whom 171 were eligible. Patients received IRN 50 mg\/m<jats:sup>2<\/jats:sup>\/d for 5 days repeated every 3 weeks. Pharmacokinetic studies and UGT1A1 genotyping were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 161 patients assessable for response, one patient with hepatoblastoma had a complete response, with partial responses observed in patients with medulloblastoma (n = 4), rhabdomyosarcoma (n = 1), neuroblastoma (n = 1), and germinoma (n = 1), for an overall response rate of 5%. Grade 4 neutropenia and grade 3 to 4 diarrhea occurred in less than 7% of the courses administered. Pharmacokinetic studies were available for 79 patients. The mean \u00b1 standard deviation IRN plasma clearance was 374 \u00b1 148 mL\/min\/m<jats:sup>2<\/jats:sup>, with median relative extent of conversion and relative extent of glucuronidation of 0.05 (range, 0.01 to 0.25) and 2.24 (range, 0.39 to 9.6), respectively. No association between UGT1A1 genotype (n = 61) and toxicity or pharmacokinetic parameters was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>IRN 50 mg\/m<jats:sup>2<\/jats:sup>\/d for 5 days every 21 days is well tolerated, but was not effective as a single agent in a spectrum of solid tumors, with the possible exception of patients with medulloblastoma (16% response rate). There was no association between UGT1A1*28 genotype and toxicity or pharmacokinetic parameters.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2007.11.6103","type":"journal-article","created":{"date-parts":[[2007,10,9]],"date-time":"2007-10-09T22:24:24Z","timestamp":1191968664000},"page":"4622-4627","source":"Crossref","is-referenced-by-count":132,"title":["Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study"],"prefix":"10.1200","volume":"25","author":[{"given":"Lisa R.","family":"Bomgaars","sequence":"first","affiliation":[{"name":"From the Baylor College of Medicine, Houston, TX; IWK Health Centre, Halifax, Nova Scotia, Canada; Keck School of Medicine, University of Southern California, Los Angeles; Rady Children's Hospital, San Diego; Children's Oncology Group, Arcadia, CA; University of Chicago, Chicago, IL; and Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bernstein","sequence":"additional","affiliation":[{"name":"From the Baylor College of Medicine, Houston, TX; IWK Health Centre, Halifax, Nova Scotia, Canada; Keck School of Medicine, University of Southern California, Los Angeles; Rady Children's Hospital, San Diego; Children's Oncology Group, Arcadia, CA; University of Chicago, Chicago, IL; and Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Krailo","sequence":"additional","affiliation":[{"name":"From the Baylor College of Medicine, Houston, TX; IWK Health Centre, Halifax, Nova Scotia, Canada; Keck School of Medicine, University of Southern California, Los Angeles; Rady Children's Hospital, San Diego; Children's Oncology Group, Arcadia, CA; University of Chicago, Chicago, IL; and Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kadota","sequence":"additional","affiliation":[{"name":"From the Baylor College of Medicine, Houston, TX; IWK Health Centre, Halifax, Nova Scotia, Canada; Keck School of Medicine, University of Southern California, Los Angeles; Rady Children's Hospital, San Diego; Children's Oncology Group, Arcadia, CA; University of Chicago, Chicago, IL; and Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Das","sequence":"additional","affiliation":[{"name":"From the Baylor College of Medicine, Houston, TX; IWK Health Centre, Halifax, Nova Scotia, Canada; Keck School of Medicine, University of Southern California, Los Angeles; Rady Children's Hospital, San Diego; Children's Oncology Group, Arcadia, CA; University of Chicago, Chicago, IL; and Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjia","family":"Chen","sequence":"additional","affiliation":[{"name":"From the Baylor College of Medicine, Houston, TX; IWK Health Centre, Halifax, Nova Scotia, Canada; Keck School of Medicine, University of Southern California, Los Angeles; Rady Children's Hospital, San Diego; Children's Oncology Group, Arcadia, CA; University of Chicago, Chicago, IL; and Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Adamson","sequence":"additional","affiliation":[{"name":"From the Baylor College of Medicine, Houston, TX; IWK Health Centre, Halifax, Nova Scotia, Canada; Keck School of Medicine, University of Southern California, Los Angeles; Rady Children's Hospital, San Diego; Children's Oncology Group, Arcadia, CA; University of Chicago, Chicago, IL; and Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Blaney","sequence":"additional","affiliation":[{"name":"From the Baylor College of Medicine, Houston, TX; IWK Health Centre, Halifax, Nova Scotia, Canada; Keck School of Medicine, University of Southern California, Los Angeles; Rady Children's Hospital, San Diego; Children's Oncology Group, Arcadia, CA; University of Chicago, Chicago, IL; and Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","unstructured":"Kaneda N, Nagata H, Furuta T, et al: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715,1990-1720,"},{"key":"R2","unstructured":"Kawato Y, Aonuma M, Hirota Y, et al: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187,1991-4191,"},{"key":"R3","unstructured":"Houghton PJ, Cheshire PJ, Hallman JC, et al: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 53:2823,1993-2829,"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686188"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Hare CB, Elion GB, Houghton PJ, et al: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 39:187,1997-191,","DOI":"10.1007\/s002800050558"},{"key":"R6","unstructured":"Thompson J, Zamboni WC, Cheshire PJ, et al: Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 3:423,1997-431,"},{"key":"R7","unstructured":"Blaney S, Berg SL, Pratt C, et al: A phase I study of irinotecan in pediatric patients: A pediatric oncology group study. Clin Cancer Res 7:32,2001-37,"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1815"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20355"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.175"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200202000-00007"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI915"},{"key":"R13","unstructured":"Rivory LP, Riou JF, Haaz MC, et al: Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 56:3689,1996-3694,"},{"key":"R14","unstructured":"Haaz MC, Rivory L, Riche C, et al: Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions. Cancer Res 58:468,1998-472,"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Dodds HM, Haaz MC, Riou JF, et al: Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 286:578,1998-583,","DOI":"10.1016\/S0022-3565(24)37620-7"},{"key":"R16","unstructured":"Santos A, Zanetta S, Cresteil T, et al: Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 6:2012,2000-2020,"},{"key":"R17","unstructured":"Gupta E, Lestingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54:3723,1994-3725,"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.14.8170"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511023331802"},{"key":"R20","unstructured":"Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 60:6921,2000-6926,"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004267159"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.07.016"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0548"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602042"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1007\/BF00689205"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200005150-00024"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21629"},{"key":"R28","unstructured":"Ma MK, Zamboni WC, Radomski KM, et al: Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin Cancer Res 6:813,2000-819,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2007.11.6103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T14:26:57Z","timestamp":1737469617000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.11.6103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,10]]},"references-count":28,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2007,10,10]]}},"alternative-id":["10.1200\/JCO.2007.11.6103"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.11.6103","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,10]]}}}